NEW YORK – When patients are diagnosed with early-stage, asymptomatic chronic lymphocytic leukemia (CLL), current international guidelines recommend they undergo active surveillance and proceed with interventional treatment only once their disease begins to progress.
But for the roughly 70 percent of patients who present with early-stage disease, it's difficult to anticipate how long it might be before progression occurs, making interventional treatment necessary.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
